Ability of clinical grade to predict final Pathologic stage in upper urinary tract transitional cell carcinoma: Implications for therapy

被引:89
作者
Brown, Gordon A.
Matin, Surena F.
Busby, J. Erik
Dinney, Colin P. N.
Grossman, H. Barton
Pettaway, Curtis A.
Munsell, Mark F.
Kamat, Ashish M.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
关键词
D O I
10.1016/j.urology.2007.03.051
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To evaluate whether the clinical grade predicts the final pathologic stage in upper urinary tract transitional cell carcinoma. METHODS We retrospectively reviewed the records of 184 consecutive patients undergoing nephroureterectomy for upper urinary tract transitional cell carcinoma at our institution from 1986 to 2004. Their clinical, surgical, and pathologic data were reviewed to determine the positive and negative predictive values of the clinical biopsy grade with respect to the final pathologic disease stage. RESULTS Of the 184 patients, 119 (64.7%) had information available regarding the clinical grade of disease from the preoperative endoscopic biopsy. The distribution was grade I in 2 (1.6%), grade 2 in 46 (38.7%), and grade 3 in 71 (59.7%) patients. Of the 71 patients with grade 3 disease, 47 had Stage pT2 disease or higher (66% positive predictive value). Of the 48 patients with less than grade 3 disease, 35 had less than pT2 disease (72% negative predictive value). Of the 71 patients with grade 3 disease, 30 had pT3 disease or greater (42% positive predictive value), and of the 48 patients with less than grade 3 disease, 44 had less than pT3 disease (92% negative predictive value). CONCLUSIONS The histologic grade obtained from the diagnostic biopsy for upper urinary tract transitional cell carcinoma can be used to predict the pathologic disease stage. This information can be used to counsel patients before surgery and to identify patients for whom neoadjuvant chemotherapy Would be most beneficial.
引用
收藏
页码:252 / 256
页数:5
相关论文
共 10 条
[1]   Combining surgery and chemotherapy for invasive bladder cancer: current and future directions [J].
Amiel, Gilad E. ;
Lerner, Seth P. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (02) :281-291
[2]   TRANSITIONAL CELL-CARCINOMA OF THE UPPER URINARY-TRACT - EVALUATION OF PROGNOSTIC FACTORS BY HISTOPATHOLOGY AND FLOW CYTOMETRIC ANALYSIS [J].
CORRADO, F ;
FERRI, C ;
MANNINI, D ;
CORRADO, G ;
BERTONI, F ;
BACCHINI, P ;
LELLI, G ;
LIEBER, MM ;
SONG, JM .
JOURNAL OF UROLOGY, 1991, 145 (06) :1159-1163
[3]   The World Health Organization International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder [J].
Epstein, JI ;
Amin, MB ;
Reuter, VR ;
Mostofi, FK .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1998, 22 (12) :1435-1448
[4]   Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J].
Grossman, HB ;
Natale, RB ;
Tangen, CM ;
Speights, VO ;
Vogelzang, NJ ;
Trump, DL ;
White, RWD ;
Sarosdy, MF ;
Wood, DP ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :859-866
[5]   Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: A 30-year experience in 252 patients [J].
Hall, MC ;
Womack, S ;
Sagalowsky, AI ;
Carmody, T ;
Erickstad, MD ;
Roehrborn, CG .
UROLOGY, 1998, 52 (04) :594-601
[6]   NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED UROTHELIAL CANCER OF THE UPPER URINARY-TRACT [J].
IGAWA, M ;
URAKAMI, S ;
SHIINA, H ;
KISHI, H ;
HIMENO, Y ;
ISHIBE, T ;
USUI, T .
UROLOGIA INTERNATIONALIS, 1995, 55 (02) :74-77
[7]   Diagnostic accuracy of ureteroscopic biopsy in upper tract transitional cell carcinoma [J].
Keeley, FX ;
Kulp, DA ;
Bibbo, M ;
McCue, PA ;
Bagley, DH .
JOURNAL OF UROLOGY, 1997, 157 (01) :33-37
[8]   Transitional cell carcinoma of the ureter and renal pelvis [J].
Kirkali, Z ;
Tuzel, E .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 47 (02) :155-169
[9]  
Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO
[10]  
2-9